Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06742190 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | PHASE3 | ACTIVE NOT_RECRUITING | 154 | — | — | Dec 18, 2024 | Dec 1, 2029 | May 20, 2026 | 109 | United States, Australia +24 |
| NCT07610564 | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy | PHASE1 | NOT YET_RECRUITING | 60 | — | — | Jun 30, 2026 | Apr 1, 2030 | May 28, 2026 | - | — |
CSA : cross-sectional area
| Arm | Type | Description |
|---|---|---|
| Part A - empasiprubart + IVIg-placebo | EXPERIMENTAL | During the double blinded - double dummy part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm |
| Part A - IVIg + empasiprubart-placebo | ACTIVE_COMPARATOR | During the double blinded - double dummy part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm |
| Part B - empasiprubart | EXPERIMENTAL | After completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg) |
| Empasiprubart IV | EXPERIMENTAL | Participants receive empasiprubart IV |
| Name | Type | Description |
|---|---|---|
| Empasiprubart | BIOLOGICAL | Intravenous infusion of empasiprubart |
| IVIG (Intravenous Immunoglobulin) | BIOLOGICAL | Intravenous infusion of IVIg |
| Empasiprubart-placebo | OTHER | A placebo resembling the empasiprubart treatment |
| IVIg-placebo | OTHER | A placebo resembling the IVIg treatment |
| Empasiprubart IV | BIOLOGICAL | Intravenous infusions of empasiprubart |
Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent for clinical studies * Has a confirmed diagnosis of definite or probable MMN at screening according to the EFNS/PNS 2010 guidelines * Has responded to IVIg in the past 5 years. * Is receiving IVIg at a treatment in...